To access the full text documents, please follow this link: http://hdl.handle.net/2445/105206
dc.contributor.author | Ruíz Martínez, Marc |
---|---|
dc.contributor.author | Navarro Ponz, Alfons |
dc.contributor.author | Marrades Sicart, Ramon Ma. |
dc.contributor.author | Viñolas Segarra, Núria |
dc.contributor.author | Santasusagna, Sandra |
dc.contributor.author | Muñoz García, Carmen |
dc.contributor.author | Ramírez Ruz, J. (José) |
dc.contributor.author | Molins López-Rodó, Laureano |
dc.contributor.author | Monzó Planella, Mariano |
dc.date | 2017-01-02T16:55:36Z |
dc.date | 2017-01-02T16:55:36Z |
dc.date | 2016-06-06 |
dc.date | 2017-01-02T16:55:41Z |
dc.identifier | 1949-2553 |
dc.identifier | 663235 |
dc.identifier | 27285987 |
dc.identifier.uri | http://hdl.handle.net/2445/105206 |
dc.description | BACKGROUND: Cancer-derived exosomes are involved in metastasis. YKT6 is a SNARE protein that participates in the regulation of exosome production and release, but its role in non-small cell lung cancer (NSCLC) has not been examined. MATERIALS AND METHODS: Ultracentrifugation-purified exosomes from the A549 cell line were studied by CRYO-TEM, nanoparticle tracking analysis and western blot (TSG101 marker). YKT6 was inhibited using a DsiRNA and selected pre-microRNAs. MicroRNAs targeting YKT6 were validated by Renilla/Luciferase assay and western blot. YKT6 expression and its prognostic impact were analyzed in 98 tissue specimens from resected NSCLC patients. RESULTS: Membranous nanosized vesicles (mode size: 128nm) with TSG101 protein were purified from A549 cells. YKT6 inhibition reduced exosome release by 80.9%. We validated miR-134 and miR-135b as miRNAs targeting YKT6, and transfection with the pre-miRNAs also produced a significant reduction in exosome release. The analysis of YKT6 in tumor samples showed that patients with high levels had shorter disease-free and overall survival. CONCLUSIONS: YKT6 is a key molecule in the regulation of exosome release in lung cancer cells and is in turn precisely regulated by miR-134 and miR-135b. Moreover, YKT6 levels impact prognosis of resected NSCLC patients. |
dc.format | 10 p. |
dc.format | application/pdf |
dc.language | eng |
dc.publisher | Impact Journals |
dc.relation | Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.9862 |
dc.relation | Oncotarget, 2016, vol. 7, num. 32, p. 51515-51524 |
dc.relation | https://doi.org/10.18632/oncotarget.9862 |
dc.rights | cc-by (c) Ruíz Martínez, Marc et al., 2016 |
dc.rights | http://creativecommons.org/licenses/by/3.0/es |
dc.rights | info:eu-repo/semantics/openAccess |
dc.subject | Càncer de pulmó |
dc.subject | Proteïnes citosquelètiques |
dc.subject | Micro RNAs |
dc.subject | Lung cancer |
dc.subject | Cytoskeletal proteins |
dc.subject | MicroRNAs |
dc.title | YKT6 expression, exosome release, and survival in non-small cell lung cancer |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/publishedVersion |